Zenas BioPharma reports Q2 2026 results, obexelimab BLA now accepted by FDAAug 13Quarterly updateobexelimabZenas BioPharma (USA), LLC
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Sign inSign in